EXEL - Exelixis, Inc.
Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
As of May 15, 2026: spot at $50.18, ATM IV 37.2%, max pain $45.00, net GEX $4.9M.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $12.89B
- P/E Ratio
- 15.90
- Beta
- 0.39
- 52-Week Range
- 33.76-51.48
- CEO
- Michael Morrissey
- Employees
- 1,147
- IPO Date
- Apr 17, 2000
- Exchange
- NASDAQ
What EXEL Looks Like to Options Traders Today
IV rank of 40.5% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($4.9M) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.008) is roughly flat across the wings.
What This Page Covers
The EXEL overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked EXEL overview questions
- What is EXEL?
- EXEL is the ticker symbol for Exelixis, Inc., a listed security. Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Listed on NASDAQ. EXEL is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the EXEL options snapshot look like today?
- As of May 15, 2026, the EXEL options snapshot shows spot at $50.18, ATM IV 37.2%, IV rank 40.5%, max pain $45.00, net GEX $4.9M, expected move 10.66%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are EXEL's key statistics?
- Exelixis, Inc. (EXEL) carries a market capitalization of $12.89B, trailing P/E ratio of 15.90, beta of 0.39 relative to the broader market, 52-week range of 33.76-51.48. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does EXEL belong to?
- Exelixis, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare EXEL's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the EXEL data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).